Prelude Therapeutics Incorporated
PRLD
$5.55
$0.193.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 51.34% | 39.14% | 21.76% | 15.01% | 4.26% |
| Total Depreciation and Amortization | -9.93% | -6.40% | -3.44% | 10.41% | 18.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -47.63% | -40.68% | -28.53% | -30.62% | -17.53% |
| Change in Net Operating Assets | 701.72% | 748.19% | 573.84% | -221.28% | -176.18% |
| Cash from Operations | 69.31% | 58.46% | 45.28% | 5.26% | -4.07% |
| Capital Expenditure | 100.00% | 96.17% | 91.23% | 93.48% | 92.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -172.37% | -100.17% | -41.15% | 75.19% | 29.40% |
| Cash from Investing | -172.50% | -100.19% | -40.73% | 79.29% | 33.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 90.36% | 47.34% | -47.13% | -428.13% |
| Issuance of Common Stock | 42,245.59% | 5,637.30% | 5,604.10% | -99.15% | -98.94% |
| Repurchase of Common Stock | -174.07% | -46.51% | 68.52% | 60.42% | 47.06% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -17,826.92% | -167.27% | -- | 100.00% | 69.05% |
| Cash from Financing | 38,448.96% | 9,371.43% | 20,780.00% | -100.64% | -101.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 97.01% | -224.16% | 271.44% | 847.35% | -250.22% |